# SHY Therapeutics

Source: https://onco.cc/companies/shy-therapeutics/  
OnCo record `shy-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SHY Therapeutics develops small-molecule medicines taken by mouth. Its lead, SHY-ONC6, blocks part of the proteasome, the cell's protein-recycling machine, and is in an early trial in advanced solid tumours.

## Summary

SHY Therapeutics, LLC, of Valhalla, New York, with laboratory work on the New York Medical College campus, develops small molecules from a proprietary platform of pharmacophores that non-covalently modulate ATPases and GTPases. Its lead, SHY-ONC6, is described as an oral small-molecule inhibitor of proteasome ATPases; the company announced in August 2026 that the first patient had been dosed in its phase 1 trial, Luca-1 (NCT07705334), which gives SHY-ONC6 once daily in 21-day cycles to adults with advanced or metastatic solid tumours including triple-negative and HR-positive breast, colon and gastric cancers. Its pipeline also includes a multi-target Ras superfamily GTPase cancer programme in lead optimisation and non-oncology programmes in anti-infectives and neuromuscular disease. Its first registered cancer trial, NCT07705334, was posted on ClinicalTrials.gov in July 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: SHY Therapeutics, LLC
- HQ: Valhalla, NY
- Type: biotech
- Website: https://www.shytherapeutics.com/

## Notes

- OnCo has no technology record for proteasome inhibitors; the link to cytotoxic chemotherapy is the nearest fit and should be revisited.
- Founding year and financing not stated on the company website; the launch release linked from the website returned HTTP 404 on 29 October 2026.

## Sources

- Official website: https://www.shytherapeutics.com/
- First patient dosed with SHY-ONC6, August 2026: https://www.shytherapeutics.com/news/shy-therapeutics-first-patient-dosed-in-phase-1-clinical-trial
- ClinicalTrials.gov: phase 1 trial of SHY-ONC6 (NCT07705334): https://clinicaltrials.gov/study/NCT07705334

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [Proteasome (PSMB5)](https://onco.cc/targets/proteasome/)

---
JSON: https://onco.cc/api/v1/entities/shy-therapeutics.json